.png)
In another exciting week for Medtech companies in the LSI Alumni community, we saw LSI Alumni raise Series B & C funding rounds, receive multiple FDA 510(k) clearances, enter new partnerships, and much more on the road to LSI Europe '24 in Sintra, Portugal this September.
Entered a strategic partnership with Bracco Imaging S.p.A., a global leader in the field of diagnostic imaging solutions. Under this exclusive agreement, Bracco will manufacture a microbubble solution for use with BURL Concepts' revolutionary SONAS® device, a portable, battery-powered ultrasound system for non-invasive assessment of blood perfusion in the brain.
Received FDA 510(k) clearance for their new IOPS® Viewpoint Catheter. The Viewpoint Catheter is the most recent addition to the company’s patented IOPS portfolio. IOPS® is commercially available and enables improved visualization and navigation in endovascular procedures.
Raised a $16M Series B funding round led by MedTech & Irrus Syndicates. The round was also joined by new investor IAG Capital Partners, alongside current investors Ascentifi, Furthr, Broadview Ventures, Atlantic Bridge University Fund, Enterprise Ireland, Elkstone and SOSV also participated.
Received FDA 510(k) clearance for Its Moda-flx Hemodialysis System. The Moda-flx Hemodialysis System provides clinicians the flexibility to easily customize each hemodialysis experience according to patient needs in one integrated system.
Completed enrollment in the AFFINITY study evaluating Aliya PEF ablation in patients with stage IV non-small cell lung cancer (NSCLC) or metastasis to the lung who are not surgical candidates. The company is developing pulsed electric field therapies for chronic bronchitis and solid tumors.
Announced the appointment of Matthew Ahearn to its Board of Directors. The company is developing the INTEGRATE-C Fusion System, the first interbody fusion cage that is fully integrated with porosity and hydroxyapatite to provide a superior healing environment.
Completed a preclinical study demonstrating the feasibility of the Symani® Surgical System in neurosurgical procedures. The company is developing the Symani® Surgical System, combining the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address unmet patient needs.
Announced the appointment of Per Vegard Nerseth as an independent non-executive director. Nerseth, the former CEO of CMR Surgical, brings more than three decades of global business experience.
Raised a $7M Series C funding round to capitalize on the company’s rapid growth and a priority on company-building to profitability. The company is developing 3D-printed spinal interbody fusion implants and instrumentation to address the existing challenges of spinal fusion.
Secured a $5M equity investment from the Bill & Melinda Gates Foundation. The company is developing a digital odor perception technology to detect disease biomarkers in the breath. The device will allow for real-time detection of serious illnesses such as cancers and infectious diseases.
Presented positive results from the two APEX randomized controlled clinical trials of the VT-X7 KIT. The company is developing a new category of combination drug/device therapies for orthopedic infections.
Announced the final close of its Series A extension round raising an additional $3 million in an oversubscribed funding round, bringing the total funding to $9 million. The round was supported by new investors cultivate(MD), GenHenn Capital, and Houston Angel Network, with participation from prior lead investor New World Angels.
Completed enrollment in the ACCESS 2 study, a Phase III multinational randomized clinical trial. The company is focused on improving vascular access outcomes in patients with kidney disease through their proprietary sirolimus formulation (Sirogen) for intraoperative local, perivascular drug delivery.
Signed a strategic development agreement with LSU Health New Orleans. The company's novel surgical approach uses a combination of proprietary decoupled actuators and immersive reality to transport surgeons inside the patient through one incision to perform minimally invasive surgery.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in our Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
